Literature DB >> 9855614

Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology.

D Guzick1.   

Abstract

Women with polycystic ovary syndrome seek health care for 3 major reasons: infertility, menstrual irregularity, and androgen excess. The infertility is associated with anovulation. The menstrual irregularity is typically chronic, beginning with menarche. Although amenorrhea may sometimes occur, the more common presentation is irregular bleeding characteristic of anovulation. Androgen excess may be manifested by varying degrees of hirsutism. Patients may also report acne. The rapid development of virilizing signs, such as deepening of the voice, increased muscle mass, and temporal balding, should prompt a search for a tumor and lead one away from a diagnosis of polycystic ovary syndrome. Typically treatment is directed at alleviating the symptoms: ovulation induction for infertility, oral contraceptives or a progestin for menstrual irregularity, and oral contraceptives or spironolactone for hirsutism. On the basis of recent epidemiologic data suggestive of increased cardiovascular risk among women with polycystic ovary syndrome, such treatment might be complemented by a long-term approach that addresses the underlying pathophysiology of insulin resistance.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9855614     DOI: 10.1016/s0002-9378(98)70238-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Clinical review: The use of aromatase inhibitors for ovulation induction and superovulation.

Authors:  Mary Ellen Pavone; Serdar E Bulun
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

2.  Polycystic ovary syndrome and risk of uterine leiomyomata.

Authors:  Lauren A Wise; Julie R Palmer; Elizabeth A Stewart; Lynn Rosenberg
Journal:  Fertil Steril       Date:  2007-01-22       Impact factor: 7.329

3.  Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome.

Authors:  Jessica Carroll; Richa Saxena; Corrine K Welt
Journal:  J Pediatr Endocrinol Metab       Date:  2012       Impact factor: 1.634

4.  Intrauterine insemination performance characteristics and post-processing total motile sperm count in relation to live birth for couples with unexplained infertility in a randomised, multicentre clinical trial.

Authors:  Karl R Hansen; Jennifer D Peck; R Matthew Coward; Robert A Wild; J C Trussell; Stephen A Krawetz; Michael P Diamond; Richard S Legro; Christos Coutifaris; Ruben Alvero; Randal D Robinson; Peter Casson; Gregory M Christman; Nanette Santoro; Heping Zhang
Journal:  Hum Reprod       Date:  2020-06-01       Impact factor: 6.353

Review 5.  Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Zeng-Hong Wu; Yun Tang; Xun Niu; Fei-Fei Pu; Xi-Yue Xiao; Wen Kong
Journal:  J Ovarian Res       Date:  2019-10-15       Impact factor: 4.234

6.  Nitric oxide (NO) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis.

Authors:  Chan Meng
Journal:  J Int Med Res       Date:  2019-08-21       Impact factor: 1.671

7.  Clomiphene citrate or letrozole as first-line ovulation induction drug in infertile PCOS women: A prospective randomized trial.

Authors:  Sujata Kar
Journal:  J Hum Reprod Sci       Date:  2012-09

Review 8.  Metformin: a review of its potential indications.

Authors:  Yi-Wei Wang; Si-Jia He; Xiao Feng; Jin Cheng; Yun-Tao Luo; Ling Tian; Qian Huang
Journal:  Drug Des Devel Ther       Date:  2017-08-22       Impact factor: 4.162

9.  N-Acetylcysteine as an Adjuvant to Letrozole for Induction of Ovulation in Infertile Patients with Polycystic Ovary Syndrome.

Authors:  Fateme Mostajeran; Hatav Ghasemi Tehrani; Bahare Rahbary
Journal:  Adv Biomed Res       Date:  2018-06-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.